Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M53,405Revenue $M6,219Net Margin (%)51.7Altman Z-Score5.3
Enterprise Value $M55,583EPS $16.4Operating Margin %26.6Piotroski F-Score6
P/E(ttm)16.3Beneish M-Score-3.0Pre-tax Margin (%)52.5Higher ROA y-yY
Price/Book5.810-y EBITDA Growth Rate %--Quick Ratio0.4Cash flow > EarningsY
Price/Sales8.55-y EBITDA Growth Rate %27.4Current Ratio0.6Lower Leverage y-yY
Price/Free Cash Flow15.1y-y EBITDA Growth Rate %73.1ROA % (ttm)22.8Higher Current Ratio y-yN
Dividend Yield %0.3PEG0.6ROE % (ttm)41.2Less Shares Outstanding y-yN
Payout Ratio %4.0Shares Outstanding M200ROIC % (ttm)18.1Gross Margin Increase y-yY

Gurus Latest Trades with SHPG

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SHPGKen Fisher 2015-06-30 Add$226.9 - $260.15
($247.87)
$ 266.818%Add 36.31%20,161
SHPGFirst Eagle Investment 2015-03-31 Add0.12%$205.66 - $253.64
($229.81)
$ 266.8116%Add 254.93%294,539
SHPGLeon Cooperman 2015-03-31 Add0.1%$205.66 - $253.64
($229.81)
$ 266.8116%Add 5.70%500,192
SHPGMario Gabelli 2015-03-31 Sold Out -0.018%$205.66 - $253.64
($229.81)
$ 266.8116%Sold Out0
SHPGKen Fisher 2015-03-31 Add$205.66 - $253.64
($229.81)
$ 266.8116%Add 1.35%14,791
SHPGLeon Cooperman 2014-12-31 Buy 1.7%$170.49 - $262.71
($211.39)
$ 266.8126%New holding473,237
SHPGJohn Paulson 2014-12-31 Reduce-0.77%$170.49 - $262.71
($211.41)
$ 266.8126%Reduce 7.93%8,328,304
SHPGDavid Tepper 2014-12-31 Sold Out -0.71%$170.49 - $262.71
($211.58)
$ 266.8126%Sold Out0
SHPGFirst Eagle Investment 2014-12-31 Add0.04%$170.49 - $262.71
($211.58)
$ 266.8126%Add 453.24%82,986
SHPGMario Gabelli 2014-12-31 Reduce-0.03%$170.49 - $262.71
($211.58)
$ 266.8126%Reduce 57.13%16,225
SHPGKen Fisher 2014-12-31 Add0.01%$170.49 - $262.71
($211.58)
$ 266.8126%Add 416.24%14,594
SHPGJohn Paulson 2014-09-30 Add6.09%$231.98 - $262.64
($248.14)
$ 266.818%Add 168.70%9,046,000
SHPGDavid Tepper 2014-09-30 Buy 0.71%$231.98 - $262.64
($248.14)
$ 266.818%New holding185,944
SHPGMario Gabelli 2014-09-30 Buy 0.05%$231.98 - $262.64
($248.14)
$ 266.818%New holding37,850
SHPGFirst Eagle Investment 2014-09-30 Buy 0.01%$231.98 - $262.64
($248.14)
$ 266.818%New holding15,000
SHPGKen Fisher 2014-09-30 Reduce$231.98 - $262.64
($248.14)
$ 266.818%Reduce 39.56%2,827
SHPGJohn Paulson 2014-06-30 Add0.84%$142.83 - $234.98
($172.9)
$ 266.8154%Add 33.07%3,366,539
SHPGKen Fisher 2014-06-30 Add$142.83 - $234.98
($172.9)
$ 266.8154%Add 91.13%4,677
SHPGJohn Paulson 2013-12-31 Reduce-0.24%$113.87 - $140.87
($131.38)
$ 266.81103%Reduce 11.03%2,529,854
SHPGJohn Paulson 2013-06-30 Add0.98%$86.59 - $99.85
($93.74)
$ 266.81185%Add 107.43%2,843,500
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SHPG is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


SHPG: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about SHPG:

News about SHPG:

Articles On GuruFocus.com
Manning & Napier's Top 5 New Stock Buys of Q2 Jul 09 2015 
Manning & Napier Invests in Stake in Baidu Jul 08 2015 
Invesco European Growth Fund Parts With Two Stakes Jul 01 2015 
Andreas Halvorsen Increases Stake in Esperion Therapeutics Jun 29 2015 
Smart Guru John Paulson Bullish on Actavis Jun 18 2015 
8 Top Healthcare Stocks to Watch May 13 2015 
John Paulson's Stocks Trading at Low P/E May 04 2015 
Shire Reports A Good Quarter Promoted By Drug Sales May 03 2015 
Top Stock Picks Among Companies That Recently Increased Dividends Mar 09 2015 
AbbVie To Acquire Biopharmaceutical Firm Pharmacyclics Mar 06 2015 

More From Other Websites
SHIRE PLC Files SEC form 10-Q, Quarterly Report Jul 30 2015
​Here are all the Boston-area biotechs about to buy or get bought Jul 29 2015
SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits Jul 29 2015
5 Health Care Stocks to Trade for Gains -- Must-See Charts Jul 28 2015
Is Now The Perfect Time To Buy Informa PLC, Banco Santander SA & Shire PLC? Jul 28 2015
Shire's (SHPG) Q2 Earnings Lag Estimates, 2015 View Raised - Analyst Blog Jul 24 2015
Which is Your Best Pharma Bet: GlaxoSmithKline plc, AstraZeneca plc Or Shire PLC? Jul 24 2015
​Here’s a graph that shows how Shire beat sales estimates for its top drug, Vyvanse Jul 23 2015
Shire Plc (SHPG) Earnings Report: Q2 2015 Conference Call Transcript Jul 23 2015
Shire Lifts 2015 Guidance On Strong Drug Pipeline Jul 23 2015
Rollercoaster day for Shire as results miss market expectations Jul 23 2015
Shire still on the hunt for acquisitions Jul 23 2015
Valeant Earnings Soar On M&A, Organic Sales Growth Jul 23 2015
Shire misses Q2 earnings forecast, raises outlook Jul 23 2015
Shire Earnings Miss Estimates as Strong Dollar Crimps Sales Gain Jul 23 2015
SHIRE PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 23 2015
Shire Announces Second Quarter Earnings and Increases Full Year Non GAAP Diluted EPS Guidance to... Jul 23 2015
Vyvanse® (lisdexamfetamine dimesylate) Positive Top-Line Results in Maintenance of Efficacy Study... Jul 22 2015
​It’s earnings season: Here are 9 local biotech firms that are actually making a profit Jul 21 2015
Could Indivior PLC Be A Better Buy Than AstraZeneca plc And Shire PLC? Jul 17 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK